Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: Vaccine compositions comprising influenza antigens formulated as nanoparticulate water in oil miniemulsions. The vaccines may be formulated at the point of use and are useful in emergency response conditions.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual ?-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: A multi-template kit system and process are described. The multi-template kit system can include a server, a database, a network, and a user device. The multi-template kit system can be implemented to provide a database of template kits having interconnected content objects. The multi-template kit process can include, but is not limited to, creating a kit having a plurality of templates. Each of the templates can include on or more content objects. When a content object is included in more than one template, each time the content object is updated, the update can be applied to each template having the content object. As such, updates can be made to each template included in the kit when a content object is updated.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: An in-situ communication customization system and process are described. The communication customization system and process can be implemented to create a communication based on previewing the communication in context of where the communication will be displayed. Typically, a smart device can be implemented to generate a live image of where the communication will be placed, and then integrating a graphical representation of the communication with the live image of the display location. The communication can then be altered based on design options, with the smart device re-rendering the graphical representation of the communication based on alterations by a user.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: A marketing display customization system and process are described. The marketing display customization system can include a server, a plurality of databases, a network, and a user device. The marketing display customization system can be implemented to provide a database of chassis templates having one or more rules and/or constraints. The system can be implemented to create a bill of material for a marketing display by selecting one or more display items from a display item database and selecting content for one or more design elements from a design element database. The marketing display customization process can include, but is not limited to, selecting a chassis template, selecting one or more display items for the chassis template, and defining one or more design elements of the chassis template to create a marketing display.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: A multi-template kit system and process are described. The multi-template kit system can include a server, a database, a network, and a user device. The multi-template kit system can be implemented to provide a database of template kits having interconnected content objects. The multi-template kit process can include, but is not limited to, creating a kit having a plurality of templates. Each of the templates can include on or more content objects. When a content object is included in more than one template, each time the content object is updated, the update can be applied to each template having the content object. As such, updates can be made to each template included in the kit when a content object is updated.

Abstract: A multi-channel queue system and process are described. The multi-channel queue system can include a server, a template database, a network, one or more user devices, and a document database. The multi-channel queue process can include, but is not limited to, creating a plurality of documents targeted to a variety of demographics and storing the plurality of documents in a database communicatively coupled to one or more communication systems.

Abstract: A template metadata system and a process for attaching descriptive information to metadata of a template are described. The template metadata process can include, but is not limited to, characterizing template properties for purposes of finding, filtering, organizing, and processing a database of templates. The template metadata system includes a server, a template database, a network, and an end user device. In one embodiment, the template metadata system can generate input parameters for discovering a pre-existing template from among a collection of templates stored in a template database.

Abstract: A content analytics system and method are described. The content analytics system can include a server, an asset database, a network, an end user device, and a behavioral analytics data repository. The content analytics process can include, but is not limited to, attaching dynamic, event-based, behavioral analytics data associated with communications initiatives to an asset.

Abstract: Vaccine compositions comprising influenza antigens formulated as nanoparticulate water in oil miniemulsions. The vaccines may be formulated at the point of use and are useful in emergency response conditions.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual ?-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention.

Abstract: The invention concerns therapeutic vaccine compositions that comprise modified Insulin B chain components suitable for use as immunogenic agents for treatment and prevention of Type 1 Diabetes.